Table 1.
Hemodynamic effects of AS infusion
| Hemodynamics | Baseline (n = 9) | NO− (n = 9) | NAC (n = 6) | NAC + NO− (n = 6) |
|---|---|---|---|---|
| Heart rate, bpm | 134 ± 4 | 141 ± 5.5 | 150 ± 7 | 155 ± 7 |
| Ees, mmHg/s | 10.46 ± 1.5 | 19.5 ± 3.8* | 10.7 ± 0.6* | 12.1 ± 1.3† |
| DEDV | 100.2 ± 16 | 177.3 ± 19‡ | 125.4 ± 29* | 141.6 ± 26† |
| SVR, mmHg/mm | 7.28 ± 0.3 | 7.33 ± 0.5 | 5.9 ± 0.21 | 5.22 ± 0.25§¶ |
| Tau (dP/dt), ms | 31.1 ± 1.3 | 28.4 ± 1‡ | 29.6 ± 1 | 31.1 ± 2.2¶ |
| LVPes, mmHg | 132.4 ± 6 | 109.5 ± 5‡ | 119.4 ± 5.5 | 108 ± 5.6§ |
| LVEDV, ml | 37.3 ± 2 | 34.8 ± 2‡ | 36.5 ± 1.35 | 33.8 ± 1.2§ |
| LVEDP, mmHg | 10.6 ± 3 | 3.6 ± 2* | 9.8 ± 3.7 | 2.2 ± 2.7§ |
| CorF, ml/min | 52.5 ± 6.1 | 45.4 ± 5.8 | 64.4 ± 7.7 | 66.7 ± 10.3 |
Data are means ± SEM. NO−, nitroxyl anion; NAC, N-acetylcysteine; Ees, slope of the end-systolic pressure–dimension relation; DEDV, preload-normalized maximal dP/dt; SVR, systemic vascular resistance; Tau, time constant of relaxation; LVPes, LV end-systolic pressure; LVEDV, LV end-diastolic volume; LVEDP, LV end-diastolic pressure; CorF, coronary blood flow (circumflex territory).
*
, P < 0.01 vs. baseline. †, P ≤ 0.01. ‡, P < 0.005 vs. baseline. §, P < 0.05 vs. NAC only. ¶, P = 0.06 for comparison of NO− effect with or without NAC.